

#11/Rew
04/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 09/895,072

GAU: 1652

FILED: July 2, 2001

EXAMINER: Patterson

FOR: METHODS FOR PRODUCING HIGHLY PHOSPHORYLATED LYSOSOMAL HYDROLASES

#11
Entered
4/23/03
LKB

TERMINAL DISCLAIMER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Now comes the undersigned, Attorney of Record in the present application, who avers as follows:

Genzyme Glycobiology Research Institute, Inc., is the owner of the entire right, title and interest in and to the invention claimed and disclosed in the above-captioned patent application by virtue of assignment, a copy of the Assignment is attached hereto, and said copy is a true and accurate copy of the Assignment as filed in the U.S. Patent and Trademark Office.

Genzyme Glycobiology Research Institute, Inc., hereby disclaims the terminal part of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of Patent No. 6,534,300, and hereby agrees that any patent so granted on said above-captioned application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent No. 6,534,300, this agreement to run with any patent granted on the above-captioned application and to be binding upon the grantee, its successors or assigns.

Genzyme Glycobiology Research Institute, Inc., does not disclaim any terminal part of any patent granted on the above-captioned application that would extend to the full statutory term as presently shortened by any terminal disclaimer of Patent No. 6,534,300 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Richard L. Chinn

Registration No. 34,305

04/08/2003 JBALINAN 00000033 09895072
110.00 OP
02 FC:1814

4-04-03

Date Signed

COPY

OSMM&N File No. 23 US-2SD
Serial No. 09/636,596 (first of 11)
Patent No. _____

Dept.: KLH
By: MJS/abd

In the matter of the Application of: NOVATYME PHARMACEUTICALS, INC.
For: COPORATE NAME CHANGE

The following has been received in the U.S. Patent Office on the date stamped hereon:

- Check for \$440.00
- Certified Certificate of Amendment and Recordation Cover Sheet (PTO-1595) 3 pages



RECEIVED

APR 09 2003

TECH CENTER 1600/2900

To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): NOVAZYME PHARMACEUTICALS, INC.	2. Name and address of receiving party(ies): Name: GENZYME GLYCOBIOLOGY RESEARCH INSTITUTE, INC. Address: 800 Research Parkway Suite 200 Oklahoma City, Oklahoma 73014
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
3. Nature of Conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Change of Name <input type="checkbox"/> Other Execution Date: May 21, 2002	Additional name(s) and address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

09/636,596	10/023,888
09/636,060	09/895,072
09/636,077	09/986,552
09/635,872	10/023,894
10/023,890	10/024,197
10/023,889	

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:



22850

6. Total applications and patents involved: 11

7. Total fee (37 CFR 3.41): \$440.00

 Enclosed Authorized to be charged to deposit account8. Deposit account number: 15-0030
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Marvin J. Spivak

Name of Person Signing

Signature

Date

Registration Number: 24,913

Total number of pages including this cover sheet: 3

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
Box Assignments
Washington, D.C. 20231

210119US-0001

Delaware


PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "NOVAZYME PHARMACEUTICALS, INC.", CHANGING ITS NAME FROM "NOVAZYME PHARMACEUTICALS, INC." TO "GENZYME GLYCOBIOLOGY RESEARCH INSTITUTE, INC", FILED IN THIS OFFICE ON THE TWENTY-SECOND DAY OF MAY, A.D. 2002, AT 3:15 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State



3275898 8100

020327648

AUTHENTICATION: 1792285

DATE: 05-23-02

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION

* * * * *

Novazyme Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said corporation by the unanimous written consent of its members, filed with the minutes of the Board, adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation of said corporation:

RESOLVED, that the Certificate of Incorporation of Novazyme Pharmaceuticals, Inc. be amended by changing the First Article thereof so that, as amended, said Article shall be and read as follows:

"The name of the corporation is Genzyme Glycobiology Research Institute, Inc."

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent to said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.

THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

FOURTH: That this Certificate of Amendment of the Certificate of Incorporation shall be effective on June 1, 2002.

IN WITNESS WHEREOF, said Novazyme Pharmaceuticals, Inc. has caused this certificate to be signed by Joanne M. Vasily-Cioffi, its Assistant Secretary, this 21st day of May, 2002.

By Joanne M. Vasily-Cioffi
Joanne M. Vasily-Cioffi
Assistant Secretary